Lung Cancer | Specialty

ESMO 2019: Dr. O'Shaughnessy Highlights Progress in Breast Cancer

September 29th 2019

ESMO 2019: Dr. Choueiri Discusses Novel Treatment Strategies in GU Cancers

September 29th 2019

ESMO 2019: Dr. Hamid Discusses Exciting Immunotherapy Data in Melanoma

September 29th 2019

ESMO 2019: Dr. Ramalingam Discusses Confirmatory Data in Advanced NSCLC

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 3

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 2

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 1

September 29th 2019

Dr. Ramalingam on the OS Results of the FLAURA Trial in EGFR-Mutant NSCLC

September 28th 2019

Suresh S. Ramalingam, MD, discusses the overall survival (OS) results of the phase III FLAURA trial in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Osimertinib OS Data Herald New Frontline Standard for EGFR-Mutant NSCLC

September 28th 2019

Frontline treatment with osimertinib improved median overall survival by 6.8 months compared with erlotinib or gefitinib for patients with metastatic, EGFR-mutant non–small cell lung cancer.

Dr. Chow on the Use of Ceritinib in ALK+ NSCLC Metastatic to the Brain

September 28th 2019

Laura Quan Man Chow, MD, FRCPC, discusses the use of ceritinib (Zykadia) in patients with ALK-positive non–small cell lung cancer that has metastasized to the brain.

Combo Strategies, Sequencing Research Ongoing in EGFR-Mutant NSCLC

September 26th 2019

Raja Mudad, MD, FACP, discussed the available EGFR inhibitors and sequencing challenges for patients with EGFR-mutant non-small cell lung cancer.

Biomarkers Require Refining in Lung Cancer Paradigm

September 25th 2019

Hossein Borghaei, DO, discusses pivotal and ongoing trials driven by biomarkers in lung cancer.

Immunotherapy Is Shifting Role of Chemotherapy in Squamous NSCLC

September 24th 2019

Luis E. Raez, MD, discusses major trials in squamous NSCLC and what lies ahead for immunotherapy.

Genetic Testing Throughout Disease Course Critical in Lung Cancer

September 24th 2019

Konstantinos Leventakos, MD, discusses updates in personalized medicine for patients with stage III lung cancer.

Dr. Leach on Brigatinib in ALK-Positive NSCLC

September 21st 2019

Joseph Leach, MD, medical oncologist at Minnesota Oncology, discusses the use of brigatinib (Alunbrig) in ALK-positive non–small cell lung cancer (NSCLC).

Osimertinib Continues to Gain Momentum as Frontline Therapy in EGFR+ NSCLC

September 19th 2019

Arek Z. Dudek, MD, PhD, discusses the research surrounding osimertinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

Building on the Momentum of the Durvalumab PACIFIC Trial in Stage III NSCLC

September 17th 2019

Naomi Fujioka, MD, discusses the clinical implications of the PACIFIC trial in NSCLC treatment and additional questions that are informing planned and ongoing trial designs in stage III disease.

Treatment Options for ALK+ NSCLC Continue to Grow

September 16th 2019

Joseph Leach, MD, a medical oncologist at Minnesota Oncology, discussed the emergence of ALK inhibitors in lung cancer and the importance of testing for such molecular abnormalities.

Dr. Lennes Discusses Ongoing Research on Screening Techniques for Lung Cancer

September 13th 2019

Inga T. Lennes, MD, MBA, MPH, senior vice president of Performance Improvement and Service Excellence of the Mass General Physicians Organization, medical director, Ambulatory Services, and director of clinical quality, Massachusetts General Hospital Cancer Center, discusses ongoing research on screening techniques for lung cancer.

Liposomal Irinotecan Active in Small Cell Lung Cancer

September 13th 2019

Liposomal irinotecan achieved disease control in almost half of patients as a second-line treatment for small cell lung cancer, according to findings from Part 1 of the phase II/III RESILIENT trial presented at the 2019 World Conference on Lung Cancer.